Rexahn Pharmaceuticals Presents Preliminary Efficacy Data from the Ongoing Phase IIa Clinical Trial of RX-3117 in Metastatic Bladder Cancer at the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting Jun 4, 2017
Rexahn Pharmaceuticals to Present RX-3117 Clinical Data at the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting May 8, 2017
Rexahn Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update May 4, 2017
Rexahn Pharmaceuticals Reports Full Year 2016 Financial Results and Provides Corporate Update Feb 27, 2017
Rexahn Pharmaceuticals Doses First Patient in a Phase IIa Trial of Supinoxin™ in Patients with Metastatic Triple Negative Breast Cancer Feb 23, 2017
Rexahn Pharmaceuticals Presents an Update of the Ongoing Phase IIa Clinical Trial of RX-3117 in Metastatic Pancreatic Cancer at the American Society of Clinical Oncology (ASCO) 2017 Gastrointestinal Cancers Symposium Jan 20, 2017
Rexahn Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Corporate Update Nov 7, 2016
